Age-related Macular Degeneration (AMD) Clinical Trial
Official title:
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
Verified date | December 2021 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs. The study was conducted using the IRIS Registry, and all results were based on the study period from 01/01/2019 to 12/31/2019.
Status | Completed |
Enrollment | 331541 |
Est. completion date | November 20, 2020 |
Est. primary completion date | November 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - =1 International Classification of Diseases, Clinical Modification-9/10 CM (ICD- 9/10) code for wet AMD in 2019 - =1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or National Drug Code (NDC) code for treatment with an anti-VEGF agent (excluding brolucizumab) in 2019 - =18 years old in 2019 - =2 wet AMD-related office visits in 2019 Exclusion Criteria: - Patient eyes that received >1 type of anti-VEGF treatment on the same date - Patient eyes that did not have laterality any time during 2018-2019 - Treatment with brolucizumab during 2019 |
Country | Name | City | State |
---|---|---|---|
United States | Novartis Investigative Site | East Hanover | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients with Intraocular Inflammation (IOI) Adverse events (AEs) who were treated with anti-VEGF agents | Period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019 was assessed. | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 | |
Secondary | Age | Age information was reported | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 | |
Secondary | Gender information | Gender information was reported | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 | |
Secondary | Number of patients at various Patient Region | Patient regions: Northeast, Midwest, South, West, Unknown | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 | |
Secondary | Number of patients with Insurance type | Private, Medicare, Medicare Advantage, Medicaid, Other | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 | |
Secondary | Number of patients with Laterality of wet Age-related macular degeneration (AMD) | Laterality of wet AMD: Unilateral, Bilateral | Index date (defined as the date of first injection - 01/01/2019) | |
Secondary | Number of patient eyes with the Provider specialty on date of first anti-VEGF injection | The following types were included: Retina specialist, General ophthalmologist | earliest claim of anti-VEGF injection over a one-year period from 01/012019 to 31/12/2019 | |
Secondary | Number of patient eyes treated with anti-VEGF agent | The following types were included OD [eye, right], OS [eye, left], Unspecified | Index date (defined as the date of first injection - 01/01/2019) | |
Secondary | Number of anti-VEGF injections | Anti-VEGF utilization in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period was assessed. Measured at the patient level and patient-eye level. | over a one-year period from 01/012019 to 31/12/2019 | |
Secondary | Number of patients with other ocular AEs in patients with wet AMD who were treated with anti-VEGF agents (excluding brolucizumab) | The following types were included:
Key ocular AEs IOI events RVO events Unspecified RO Autoimmune disorders (systemic lupus erythematosus [SLE], Behcet's disease, sarcoidosis, VKH disease, HLA-B27 syndromes, Drug hypersensitivity) RV without RO (RAO and/or RVO) |
over a one-year period from 01/012019 to 31/12/2019 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01694680 -
Intervention Trial in Early Age-related Macular Degeneration
|
N/A | |
Completed |
NCT01224847 -
Intravitreal Injection Anesthesia - Comparison of Different Topical Agents
|
N/A | |
Withdrawn |
NCT04697953 -
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
|
Phase 3 | |
Completed |
NCT05037396 -
Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab
|
||
Completed |
NCT00647439 -
Genetics and Markers of Degenerative and Inflammatory Eye Diseases
|
||
Terminated |
NCT00902785 -
A Study Of Early Markers Of Choroidal Neovascularization
|
Phase 4 | |
Terminated |
NCT02348359 -
X-82 to Treat Age-related Macular Degeneration
|
Phase 2 | |
Recruiting |
NCT03690505 -
Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
|
N/A | |
Recruiting |
NCT03577041 -
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
|
||
Completed |
NCT05082415 -
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study)
|
||
Completed |
NCT02445313 -
Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device
|
||
Recruiting |
NCT00354445 -
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
|
Phase 4 | |
Completed |
NCT05111743 -
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
|
||
Terminated |
NCT02398500 -
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT05146687 -
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
|
||
Not yet recruiting |
NCT05780931 -
Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
|
||
Recruiting |
NCT04292080 -
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
|
Phase 2 | |
Recruiting |
NCT03859245 -
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
|
N/A | |
Completed |
NCT02022540 -
Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
|
Phase 1 | |
Completed |
NCT02585401 -
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
|
N/A |